Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan vs Hydrochlorothiazide in Hypertensive Patients with Metabolic Syndrome
NCT00110422Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised, double-blind trial of irbesartan in hypertension (HTN) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change from baseline in insulin resistance (Matsuda Index) at 16 weeks. Started Nov 2005; status: completed.
02
Drugs
irbesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00110422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110422.